CVB — Curvebeam AI Income Statement
0.000.00%
HealthcareMicro Cap
- AU$74.68m
- AU$74.25m
- AU$8.06m
Annual income statement for Curvebeam AI, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IFRS | IFRS | — |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0.795 | 1.67 | 8.06 |
Cost of Revenue | |||
Gross Profit | 0.795 | 1.67 | 4.39 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Other Operating Expenses | |||
Total Operating Expenses | 3.62 | 10.2 | 60.1 |
Operating Profit | -2.82 | -8.54 | -52 |
Other Net Non Operating Costs | |||
Net Income Before Taxes | -2.82 | -8.54 | -52 |
Provision for Income Taxes | |||
Net Income After Taxes | -2.82 | -8.54 | -52 |
Net Income Before Extraordinary Items | |||
Net Income | -2.82 | -8.54 | -52 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -2.82 | -8.54 | -52 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.009 | -0.027 | -0.163 |
Dividends per Share |